HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint

Executive Summary

The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.

You may also be interested in...



Statin Drug Makes SPORT Of Supplements In Pharma-Funded, 28-Day Trial On Lowering LDL

Primary and secondary endpoint results in “Supplements, Placebo, or Rosuvastatin” study conducted by Cleveland Clinic include no difference, after four weeks, in total cholesterol and blood triglyceride measures between subjects receiving placebo and those using fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice.

US Fish Oil Supplement Export Certification Program Continued 90 Days With Home TBD

NOAA Seafood Inspections Program had planned 1 May end to export certifications for fish oil supplements before granting 90-day extension as it talks with FDA about administering the program.

US Omega-3 Supplement Firm Changes Claims On Amarin Challenge, But Not Label Or Company Name

National Advertising Division, in rare review of an Rx drug firm’s challenge of supplement ad claims, reported Innovix Pharma pulled health claims for OmegaVia brand supplements challenged by Amarin. Innovix prevailed in defending its labeling as accurate and its name as not false advertising.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149511

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel